Divergent oestrogen receptor-specific breast cancer trends in Ireland (2004-2013): Amassing data from independent Western populations provide etiologic clues.

Citation data:

European journal of cancer (Oxford, England : 1990), ISSN: 1879-0852, Vol: 86, Page: 326-333

Publication Year:
Usage 16
Abstract Views 16
Captures 7
Readers 7
Social Media 4
Tweets 4
Repository URL:
https://hsrc.himmelfarb.gwu.edu/son_nurs_facpubs/255; https://hsrc.himmelfarb.gwu.edu/son_nurs_facpubs/254; https://hsrc.himmelfarb.gwu.edu/son_nurs_facpubs/249; https://hsrc.himmelfarb.gwu.edu/son_nurs_facpubs/251
Mullooly, Maeve; Murphy, Jeanne; Gierach, Gretchen L; Walsh, Paul M; Deady, Sandra; Barron, Thomas I; Sherman, Mark E; Rosenberg, Philip S; Anderson, William F
Elsevier BV
Medicine; Biochemistry, Genetics and Molecular Biology; Adult; Age Distribution; Aged; Aged; 80 and over; Biomarkers; Tumor; Breast Neoplasms; Female; Humans; Incidence; Ireland; Middle Aged; Receptor; ErbB-2; Receptors; Estrogen; Registries; Risk Factors; Time Factors; Young Adult; Medicine and Health Sciences; Nursing; Adult; Age Distribution; Aged; Aged, 80 and over; Biomarkers, Tumor; Breast Neoplasms; Female; Humans; Incidence; Ireland; Middle Aged; Receptor, ErbB-2; Receptors, Estrogen; Registries; Risk Factors; Time Factors; Young Adult
Most Recent Tweet View All Tweets
article description
The aetiology and clinical behaviour of breast cancers vary by oestrogen receptor (ER) expression, HER2 expression and over time. Data from the United States and Denmark show rising incidence rates for ER+ and falling incidence rates for ER- breast cancers. Given that Ireland is a somewhat similar Western population but with distinctive risk exposures (especially for lactation), we analysed breast cancer trends by ER status; and for the first time, by the joint expression of ER±/HER2±. We assessed invasive breast cancers (n = 24,845; 2004-2013) within the population-based National Cancer Registry of Ireland. The population at risk was obtained from the Irish Central Statistics Office (n = 10,401,986). After accounting for missing ER and HER2 data, we assessed receptor-specific secular trends in age-standardised incidence rates (ASRs) with the estimated annual percentage change (EAPC) and corresponding 95% confidence intervals (95% CI). Age-period-cohort models were also fitted to further characterise trends accounting for age, calendar-period and birth-cohort interactions. ASRs increased for ER+ (EAPC: 2.2% per year [95% CI: 0.97, 3.45%/year]) and decreased for ER- cancers (EAPC: -3.43% per year [95% CI: -5.05, -1.78%/year]), as well as for specific age groups at diagnosis (<30-49, 50-64 and ≥65 years). ER+/HER2- cancers rose, ER+/HER2+ cancers were statistically flat and ER-/HER± cancers declined. Secular trends for ER± cancers in Ireland were like those previously observed. Stratification by HER2± expression did not substantively alter ER± trends. The divergence of ER± incidence rates among independent Western populations likely reflects calendar-period and/or risk factor changes with differential effects for ER+ and ER- breast cancers.